- Previous Close
12.60 - Open
12.66 - Bid 12.73 x 200
- Ask 12.77 x 100
- Day's Range
12.59 - 12.85 - 52 Week Range
9.50 - 19.09 - Volume
802,464 - Avg. Volume
971,728 - Market Cap (intraday)
1.227B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.09 - Earnings Date Nov 6, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
24.60
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
www.avadel.com154
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AVDL
View More
Performance Overview: AVDL
Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AVDL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AVDL
View MoreValuation Measures
Market Cap
1.23B
Enterprise Value
1.16B
Trailing P/E
--
Forward P/E
12.63
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
12.31
Price/Book (mrq)
17.46
Enterprise Value/Revenue
12.17
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-111.64%
Return on Assets (ttm)
-34.44%
Return on Equity (ttm)
-99.52%
Revenue (ttm)
95.15M
Net Income Avi to Common (ttm)
-106.22M
Diluted EPS (ttm)
-1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
71.38M
Total Debt/Equity (mrq)
53.59%
Levered Free Cash Flow (ttm)
-78.18M
Research Analysis: AVDL
View MoreCompany Insights: AVDL
AVDL does not have Company Insights